Florian Markl

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.

Journal: Blood advances
Published: August 22, 2025

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Journal: Blood advances
Published: August 22, 2025

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Journal: Blood advances
Published: August 22, 2025

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.

Journal: Nature communications
Published: December 05, 2023

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.

Journal: Cancer immunology, immunotherapy : CII
Published: November 11, 2023

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Journal: Blood
Published: August 16, 2023

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Journal: Cancer immunology, immunotherapy : CII
Published: May 08, 2023

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Journal: Journal for immunotherapy of cancer
Published: April 16, 2023

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Journal: Cancer immunology, immunotherapy : CII
Published: December 18, 2022

T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.

T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.

Journal: Immunity
Published: August 20, 2022

Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.

Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.

Journal: Seminars in immunopathology
Published: July 29, 2022

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.

Journal: British journal of cancer
Published: July 29, 2022
Showing 1-12 of 16

Last Updated: 09/26/2026